Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 7, 2026, 4:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 7,427 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Jacksonville, Florida Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluation of Toric Soft Contact Lenses Containing a Chromophore to Block High-Energy Visible Light

NCT05344560
View directory record Official record
Conditions
Visual Acuity
Interventions
soft contact lens in senofilcon A (C3) with HEVL-blocking chromophore, ACUVUE OASYS 1-Day for Astigmatism
Device
Lead sponsor
Johnson & Johnson Vision Care, Inc.
Industry
Eligibility
18 Years to 39 Years
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
10
States / cities
Jacksonville, Florida • Longwood, Florida • Maitland, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2023 · Synced Jun 7, 2026, 4:28 AM EDT
Terminated Not applicable Interventional

SEMPERFLO* Pain Management System in Inguinal Hernia Repair

NCT00423241
View directory record Official record
Conditions
Inguinal Hernia, Pain
Interventions
SEMPERFLO Pain Management System, ON-Q PainBuster Post-Op Pain Relief System
Device
Lead sponsor
Ethicon, Inc.
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
6
States / cities
Boca Raton, Florida • Jacksonville, Florida • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2010 · Synced Jun 7, 2026, 4:28 AM EDT
Recruiting Not applicable Interventional

Artificial Intelligence Mapping and Ablation of Non-Pulmonary Vein Electrical Drivers of AF Study

NCT06935591
View directory record Official record
Conditions
Atrial Fibrillation (AF)
Interventions
Pulmonary Vein Isolation, vMap® + Pulmonary Vein Isolation
Procedure · Device
Lead sponsor
Vektor Medical
Industry
Eligibility
22 Years and older
Enrollment
423 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
12
States / cities
Jonesboro, Arkansas • Clearwater, Florida • Jacksonville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced Jun 7, 2026, 4:28 AM EDT
Completed Phase 2 Interventional Results available

Third Optimizing Anti-Platelet Therapy in Diabetes MellitUS (OPTIMUS-3)

NCT00642174
View directory record Official record
Conditions
Diabetes Mellitus, Coronary Artery Disease
Interventions
prasugrel, Clopidogrel
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 74 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
4
States / cities
Jacksonville, Florida • Worcester, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2010 · Synced Jun 7, 2026, 4:28 AM EDT
Completed No phase listed Observational

Tongue Pull Versus Jaw Thrust

NCT00833118
View directory record Official record
Conditions
Surgery
Interventions
Jaw thrust maneuver (Intubation)
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 11, 2010 · Synced Jun 7, 2026, 4:28 AM EDT
Completed Phase 3 Interventional Results available

Evaluating the Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their Infants

NCT03048422
View directory record Official record
Conditions
HIV Infections
Interventions
Dolutegravir, Emtricitabine/tenofovir alafenamide, Emtricitabine/tenofovir disoproxil fumarate, Efavirenz/emtricitabine/tenofovir disoproxil fumarate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older · Female only
Enrollment
643 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Jacksonville, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 20, 2022 · Synced Jun 7, 2026, 4:28 AM EDT
Completed Phase 4 Interventional

TAXUS ARRIVE 2: A Multi-Center Safety Surveillance Program

NCT00569751
View directory record Official record
Conditions
Cardiovascular Disease, de Novo Coronary Lesions
Interventions
TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent System
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
5,016 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
53
States / cities
Scottsdale, Arizona • Bakersfield, California • Rancho Mirage, California + 49 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2008 · Synced Jun 7, 2026, 4:28 AM EDT
Completed Phase 2 Interventional Results available

A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients

NCT01466790
View directory record Official record
Conditions
Hepatitis C
Interventions
TMC435, PSI-7977 (GS7977), Ribavirin
Drug
Lead sponsor
Janssen R&D Ireland
Industry
Eligibility
18 Years to 70 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
22
States / cities
Hoover, Alabama • Bakersfield, California • La Jolla, California + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2015 · Synced Jun 7, 2026, 4:28 AM EDT
Terminated Phase 3 Interventional Results available

Brexpiprazole as an Adjunctive Treatment to Paroxetine or Sertraline in Adult Patients Suffering From Post-traumatic Stress Disorder (PTSD)

NCT01987960
View directory record Official record
Conditions
Post-traumatic Stress Disorder, PTSD
Interventions
Placebo, Brexpiprazole
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 65 Years
Enrollment
417 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
22
States / cities
Los Angeles, California • Riverside, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2017 · Synced Jun 7, 2026, 4:28 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT04487080
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Amivantamab, Osimertinib, Lazertinib, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
1,074 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
20
States / cities
Goodyear, Arizona • Yuma, Arizona • Long Beach, California + 17 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Jun 7, 2026, 4:28 AM EDT
Completed Phase 3 Interventional

Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin

NCT00040027
View directory record Official record
Conditions
Hepatitis C, Hepatitis C, Chronic
Interventions
thymalfasin (thymosin alpha 1) + PEGinterferon alfa-2a, placebo + PEGinterferon alfa-2a
Drug
Lead sponsor
SciClone Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
46
States / cities
Mobile, Alabama • Scottsdale, Arizona • Berkeley, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2008 · Synced Jun 7, 2026, 4:28 AM EDT
Completed Phase 2 Interventional Results available

A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment

NCT02927769
View directory record Official record
Conditions
Hodgkin Disease
Interventions
Nivolumab, brentuximab vedotin, bendamustine
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
5 Years to 30 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
43
States / cities
Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 40 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2025 · Synced Jun 7, 2026, 4:28 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Long-Term Study Continuing on From Study 04-001-01 of an Experimental Medication in Adults With Anxiety Disorder

NCT00106860
View directory record Official record
Conditions
Anxiety Disorder
Interventions
a benzodiazepine drug
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
158 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
13
States / cities
Bradenton, Florida • Jacksonville, Florida • St. Petersburg, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2008 · Synced Jun 7, 2026, 4:28 AM EDT
Active, not recruiting Phase 3 Interventional

Oral N-acetylcysteine for Retinitis Pigmentosa

NCT05537220
View directory record Official record
Conditions
Retinitis Pigmentosa
Interventions
N-acetylcysteine, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
24
States / cities
Davis, California • Los Angeles, California • San Francisco, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Jun 7, 2026, 4:28 AM EDT
Terminated Phase 3 Interventional Results available

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

NCT01609582
View directory record Official record
Conditions
Type 2 Diabetes, Cardiovascular Disease
Interventions
TAK-875, TAK-875 Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
3,207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
218
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 215 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2015 · Synced Jun 7, 2026, 4:28 AM EDT
Completed Phase 2 Interventional Results available

A Pilot Study of KPL-914 in Recurrent Pericarditis

NCT03980522
View directory record Official record
Conditions
Recurrent Pericarditis
Interventions
KPL-914
Drug
Lead sponsor
Kiniksa Pharmaceuticals (UK), Ltd.
Industry
Eligibility
6 Years to 75 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
14
States / cities
Washington D.C., District of Columbia • DeLand, Florida • Jacksonville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated May 26, 2021 · Synced Jun 7, 2026, 4:28 AM EDT
Completed Phase 2 Interventional

Imiquimod in Preventing Cervical Cancer in Women With Cervical Neoplasia

NCT00031759
View directory record Official record
Conditions
Cervical Cancer, Precancerous Condition
Interventions
imiquimod, Ablative or excisional therapy
Drug · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2010
U.S. locations
8
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Honolulu, Hawaii + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced Jun 7, 2026, 4:28 AM EDT
Completed Phase 2 Interventional Results available

Study of Buspirone for Relapse-Prevention in Adults With Cocaine Dependence

NCT01641159
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Buspirone, Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
6
States / cities
Jacksonville, Florida • Columbus, Ohio • Philadelphia, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2015 · Synced Jun 7, 2026, 4:28 AM EDT
Completed Phase 3 Interventional Results available

Quetiapine Fumarate (SEROQUEL) in the Treatment of Adolescent Patients With Schizophrenia and Bipolar I Disorder

NCT00227305
View directory record Official record
Conditions
Schizophrenia, Bipolar I Disorder
Interventions
quetiapine fumarate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
10 Years to 17 Years
Enrollment
381 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
31
States / cities
Dothan, Alabama • Scottsdale, Arizona • Cerritos, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2013 · Synced Jun 7, 2026, 4:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Genotype Stratified Pharmacokinetic Study of Montelukast

NCT01086527
View directory record Official record
Conditions
Asthma
Interventions
10 mg tablet of montelukast (Singulair)
Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
7 Years to 35 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 9, 2025 · Synced Jun 7, 2026, 4:28 AM EDT
Completed Phase 3 Interventional

Study Evaluating Bifeprunox in Bipolar Depression

NCT00245973
View directory record Official record
Conditions
Depression Bipolar
Interventions
Bifeprunox
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
40
States / cities
Birmingham, Alabama • Beverly Hills, California • National City, California + 36 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2007 · Synced Jun 7, 2026, 4:28 AM EDT
Not listed Phase 3 Interventional

RESULT: Reliable, Emergent Solution Using Liprotamase Treatment

NCT03051490
View directory record Official record
Conditions
Exocrine Pancreatic Insufficiency, Cystic Fibrosis
Interventions
Liprotamase, porcine PERT
Drug
Lead sponsor
Anthera Pharmaceuticals
Industry
Eligibility
7 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
28
States / cities
Little Rock, Arkansas • Long Beach, California • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2018 · Synced Jun 7, 2026, 4:28 AM EDT
Active, not recruiting Not applicable Interventional

A Prospective Comparative Study of Outcomes With Proton and Photon Radiation in Prostate Cancer

NCT03561220
View directory record Official record
Conditions
Prostate Cancer
Interventions
Standard of Care IMRT (Photon), Standard of Care Proton Therapy, Proton Arm 1: Standard Proton Therapy, Proton Arm 2: Hypofractionated Proton Therapy
Radiation
Lead sponsor
University of Florida
Other
Eligibility
30 Years to 85 Years · Male only
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
53
States / cities
Birmingham, Alabama • La Jolla, California • Loma Linda, California + 44 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Jun 7, 2026, 4:28 AM EDT
Completed Phase 2 Interventional Results available

A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ)

NCT03367403
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Donanemab, Placebo, LY3202626
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
60 Years to 85 Years
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
56
States / cities
Phoenix, Arizona • Sun City, Arizona • Fullerton, California + 47 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Jun 7, 2026, 4:28 AM EDT